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Background: Acute dermatologic conditions are a concern for acute care practitioners. Comprising 
1.4% of presenting complaints to emergency departments, most skin complaints are relatively benign; 
however, some conditions can be quite severe. Prompt diagnosis is essential to avoid unnecessary 
morbidity and mortality. 
Objectives: To review drug-induced vasculitis. 
Case Report: We present the case of a 43-year-old female with a chief complaint of bruising to her 
ear, arm, and leg. She was found to have necrotizing vasculitis induced by propylthiouracil. 
Conclusion: In this case, we look at the highlights of this presentation and review key aspects of 
cutaneous vasculitis for the practicing emergency provider.
[WestJEM. 2008;9:212-215.]
INTRODUCTION
Acute dermatologic conditions are a concern for all 
healthcare professionals. With the increased national 
utilization of acute care services, emergency physicians must 
have a basic knowledge of such disorders. In 2004, “skin rash” 
complaints accounted for 1.4% of all emergency department 
(ED) visits.1 The majority of these conditions are benign and 
non-emergent, with diagnoses ranging from contact dermatitis 
to psoriasis. However, a small number of patients present with 
acute dermatologic conditions requiring rapid diagnosis and 
treatment.
Due to the multiple etiologies associated with 
dermatologic emergencies, diagnosis may often be difficult. 
However, one of the most common causes of dermatologic 
presentations to acute care facilities is a drug reaction, and 
it has been estimated that 10–20% of cutaneous reactions 
to drugs are vasculitic reactions.2,3 The prognosis for drug-
induced vasculitis is usually improved with prompt removal 
of the offending medication.4 We present a case in which 
a 43-year-old woman with a history of Graves’ disease 
presented to the ED after two weeks of progressive palpable 
purpura caused by a propylthiouracil-induced vasculitis.
CASE REPORT
A 43-year-old woman presented to the ED with a chief 
complaint of new-onset bruising. She had been well until two 
weeks prior to admission, when she developed symptoms 
consistent with an upper respiratory tract infection (URI). 
At that time the patient developed a bruise on her left calf 
without any history of trauma. As this started to resolve 
she noted some bruising on the right ear four days later. 
She complained that she was developing bruises along her 
right tricep associated with increasing redness, swelling and 
pain over these lesions. The patient denied any history of 
domestic violence, liver disease, prior bruising episodes, 
family history of bleeding disorders, heavy menses, or 
anticoagulant use. Systemically the patient denied any fevers, 
chills, chest pain, shortness of breath, abdominal pain, 
hematuria or joint complaints. Her past medical history was 
significant for Graves’ disease, which was being followed 
by her endocrinologist. She also reported degenerative joint 
disease of her left knee. Her medications included 50-mg Western Journal of Emergency Medicine                                    213                                          Volume IX, n o . 4  :  November 2008         
propylthiouracil (PTU) each day, which she has been taking 
for the past nine years. She also reported the use of 400mg 
Motrin as needed for pain relief from her arthritis. The 
patient denied taking any other medications including over-
the-counter medications for her recent URI symptoms. The 
patient stated that her mother had recently been diagnosed 
with diabetes and thyroid disease but denied any other family 
history. The patient reported a 20 pack/year tobacco history 
but denied any illicit drug use. 
On arrival to the ED she was afebrile at 36.4°C, 
with a blood pressure of 116/78 mmHg, heart rate at 74 
beats per minute, respirations at 14 breaths/minute with 
oxygen saturation at 97% on room air. On examination, 
she was a well-appearing woman in no acute distress. Her 
skin examination showed several findings. She had trace 
ecchymosis along the superior aspect of the helix of the 
right ear (Figure 1). This area was otherwise non-tender 
to palpation with no other abnormalities noted at the 
ear. She had a second ecchymotic area at her right tricep 
approximately 4 x 10 cm in diameter (Figure 2). The arm 
was tender andindurated, with some erythema at the borders 
of the lesion. There were no areas of fluctuance, and the 
neurovascular function of the arm and hand were intact. She 
also had one small left calf ecchymosis which was superficial 
and non-tender, approximately 1.5cm in diameter (Figure 3). 
Regarding the remainder of the examination, the patient’s eyes 
were normal, pupils were equally round and reactive to light, 
and no conjunctival injection was noted. The fundoscopic 
examination was unremarkable bilaterally. Lungs were clear to 
auscultation without increase in respiratory effort. The cardiac 
exam showed regular rate and rhythm without murmur, rub, 
or gallop. The abdominal examination was non-tender with 
no evidence of rebound or guarding. The rectal examination 
was normal with guiac-negative brown stool. The neurologic 
examination was unremarkable.
Laboratory analyses of CBC, coagulation studies, 
electrolytes, urinalysis, liver function tests, and negative urine 
pregnancy test were unremarkable. Blood cultures were sent 
and eventually returned negative. Erythrocyte sedimentation 
rate was elevated at 54. The patient was admitted to the 
hospital for further, assessment and subsequent lab studies 
were as follows with normal ranges in parentheses. Thyroid 
function tests showed a TSH of 1.40 uIU/mL, a free T4 of 
0.74 ng/dL (0.85-1.69), and a free T3 of 4.23 pg/mL (2.0-4.1). 
Antiphospholipid panel was negative. Anti-nuclear antibody 
screen was negative. Perinuclear-staining anti-neutrophil 
cytoplasmic antibodies (P-ANCA) was positive. Antithrombin 
III was 104% (80-120), D-dimer was 1303ng/mL (<250), and 
fibrinogen was 345 mg/dL (240-490). 
The clinical presentation of a palpable, purpuric rash 
in conjunction with elevated erythrocyte sedimentation 
rate and ANCA titers indicated a vasculitis. In general, 
the differential diagnosis for vasculitis includes infectious 
etiologies (22.1%), autoimmune disorders (4.4%), connective 
tissue disease (11.4%), malignancy (4.3%), environmental 
exposures including medications (22.7%) or idiopathic 
(39% frequency).5 In our patient, the lack of associated 
clinical symptoms and absence of other possible etiologic 
Figure 1.  Skin lesion at right pinna. Figure 2.  Skin lesion at right tricep.
Figure 3.  Skin lesion at left lower calf.
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sources lead us to believe the ANCA-positive vasculitis was 
secondary to her PTU. Previous data suggests that vasculitic 
complications associated with PTU administration have 
a varied time of onset and have been reported anywhere 
from three days to seven years from the time of initiation 
of therapy.6 Furthermore, despite conservative management 
with 60 mg prednisone per day, the patient’s symptoms did 
not resolve until several days after admission when the PTU 
therapy was discontinued. The decision to continue her PTU 
while awaiting the diagnostic workup, rather than immediately 
discontinue the medication, was made due to her lack of other 
end-organ failure often associated with vasculitis. With the 
vasculitis resolving, the patient was treated with a total course 
of oral prednisone, 60 mg each day for 10 days, along with 
metoprolol, 100mg each day for her Graves’ disease, and 
she was discharged from the hospital. The possibility of re-
challenging the patient on PTU was subsequently considered 
after her symptoms had resolved, but given the data (albeit 
limited) which suggests a high recurrence of vasculitis, it was 
felt that other treatment options should be pursued.6 
The patient returned for subtotal thyroidectomy to address 
her Graves’ disease. The surgery was uneventful, and she 
was discharged with supplementation for hypothyroidism, 
hypocalcemia, and hypomagnesemia.
DISCUSSION
Vasculitis is a rare condition among the general 
population with one study showing an estimated lifetime 
incidence of biopsy-proven vasculitis at 39.6 per million; 
however, the number varies based on geography, tertiary vs. 
outpatient setting.7 The true incidence may be higher due to 
the under-diagnosis of mild or subclinical presentations. The 
etiology of vasculitic disease can be attributed to a primary 
idiopathic process or to a secondary autoimmune syndrome, 
infectious agent, trauma, or medication. In attempting 
to determine an etiology, a proper history is essential. In 
general, drug-induced vasculitis is more likely to have 
cutaneous manifestation compared to idiopathic vasculitis.8 
And it is more likely to manifest with pulmonary and renal 
complications than musculoskeletal complaints.9 
Drug-induced vasculitis has been reported from 
penicillins, sulfonamides, allopurinol, antithyroid drugs, 
and multiple other compounds.10 Of the thyroid drugs 
propylthiouracil is the most often reported as causing drug-
induced vasculitis. Ithas also been associated with other 
rheumatic manifestations, including serum sickness and 
PTU-induced lupus.9 There is some debate whether PTU is 
the primary cause of rheumatologic disease or if the increased 
incidence is due to the underlying thyroid disease of the 
patients, which has been shown to predispose patients to other 
autoimmune conditions. PTU has been associated with various 
other inflammatory conditions, such as agranulocytosis, 
aplastic anemia, hepatitis, interstitial pneumonitis, and others. 
The mechanism of PTU-induced vasculitis is not clear. 
Studies have shown that PTU can accumulate in neutrophils. 
This may allow PTU to bind to myeloperoxidase (MPO), 
which when oxidized can inactivate this enzyme. This 
inactivation with the continued presence of PTU can induce 
the formation of auto-antibodies, thereby stimulating other 
neutrophils to degranulate, causing vascular damage.4,6,10,11,12  
Clinically the development of the MPO-ANCA antibodies 
are more prevalent in the serum of patients treated with PTU, 
and studies have demonstrated that MPO-ANCA positivity 
was increased after being treated by PTU as compared to 
other hyperthyroid medications.9,11,13 It should be noted, 
however, that not all patients with these antibodies developed 
clinical symptoms of PTU-induced rheumatic disease, which 
contraindicates the use of these auto-antibodies as a screening 
tool.14  
There are currently 44 cases of PTU-induced vasculitis 
in the literature since 2002, with an apparent female and 
Japanese-ethnic predominance.6 This gender predominance is 
likely attributed to the higher incidence of thyroid disease in 
women. It is unknown why Japanese ethnicity, which accounts 
for half of all reported cases, predisposes patients.11 There may 
be a genetic predisposition to the formation of auto-antibodies, 
or it may be caused by variations in treatment regimens. The 
age of onset varies but appears to have a higher incidence 
in younger patients; however, the reported age range is 13-
80 years old.6,14 Of note, the development of PTU-induced 
vasculitis is hypothesized to be independent of the dosage of 
PTU prescribed or the duration of PTU treatment, based on 
the limited data available.6 
The clinical presentation can be varied and complex due 
to systemic complications and multi-organ involvement of 
small-vessel disease. Signs of PTU-induced vasculitis include 
anemia (seen in the majority of patients), skin lesions (ulcers, 
purpura, subcutaneous nodules, and erythema nodosum-like 
and erythema multiforme-like lesions), arthralgia, fever, 
malaise, lymphadenopathy, hematuria/proteinuria, alveolar 
hemorrhage, and pleural effusion.4,6,14  Multiple organ systems 
can be affected, including renal failure, cholestatic jaundice, 
cardiac dysfunction, pleural effusions, pneumonitis/pleuritis, 
and hearing loss. The most common laboratory abnormalities 
include neutropenia, anemia, thrombocytopenia, and elevated 
transaminases10 (although our patient demonstrated none 
of these). Histologically the majority of patients developed 
crescentic glomerulonephritis or other forms of renal 
changes.4,14
Clinical diagnosis is often difficult because of the 
overlapping presentations of the various vasculitic diseases. 
Although biopsy is diagnostic, in most cases the diagnosis 
of drug-induced vasculitis is made by exclusion or with 
resolution of symptoms after withdrawal of medications. 
Once PTU-induced vasculitis is determined, the simple 
withdrawal of PTU usually causes resolution of the 
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symptoms after 1-4 weeks.3 Some patients have been reported 
to have continued laboratory abnormalities (elevated serum 
creatinine, proteinuria, positive ANCA titers) throughout their 
clinical follow-up without evidence of clinical symptoms.3 
Patients with more severe presentations are typically treated 
with steroids. When considering treatment for Gravesí 
disease after resolution of their symptoms, re-administration 
of PTU is not recommended because it often causes a repeat 
reaction;6,10,11 however, there does not appear to be cross-
reactivity between agents.2,10 Therefore, consideration of 
treatment should be a multi-disciplinary approach to weigh 
the risk and benefits of further medical treatment versus 
surgical intervention.
CONCLUSION 
Drug-induced vasculitis should be considered in any 
patient who takes medications and develops cutaneous 
eruptions. Emergency practitioners should be able to 
differentiate benign skin conditions from those that are 
potentially progressive, causing morbidity and possibly 
mortality.  
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